University of Pittsburgh Chancellor Patrick Gallagher’s efforts to hotwire the region’s fledgling life sciences industry is getting a spark from a new seed capital fund targeted to helping develop new medications.
The Pittsburgh Revolution Fund is soliciting $200 million, which will be made available in the form of investments in drug research teams with the idea of spinning out companies, said Bill Newlin, chairman, Newlin Investment Co., a seed-stage investment firm in Sewickley.